Related Experiment Videos
Abstract:
Following the failure of several OX40 agonist antibody candidates, findings from an early-stage trial suggest a way forward to activate the costimulatory receptor. In the trial, intratumoral injections of mRNA encoding the OX40 ligand yielded favorable immunologic and molecular effects in patients.
Insights
Intratumoral injection of messenger RNA (mRNA) encoding OX40 ligand shows promise for activating the OX40 receptor, offering a new strategy after prior antibody failures.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- OX40 agonist antibodies have faced development challenges.
- Activating the OX40 costimulatory receptor remains a key goal in cancer immunotherapy.